Findings from the phase II DYNAMIC study suggest that circulating tumor DNA analyses could help clinicians decide whether patients with stage II colon cancer require chemotherapy after standard surgery. Liquid biopsies could also shed light on the development of resistance to KRASG12C inhibition, paving the way for better treatment strategies.

You do not currently have access to this content.